Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMVT Immunovant, Inc.

Post-Mkt 10-19 16:35:54 EDT

27.62

+0.89

+3.33%

盘后27.62

+0.000.00%

16:10 EDT

High27.84	Low26.53	Vol1.38M
Open27.12	D1 Closing26.73	Amplitude4.92%
Mkt Cap5.70B	Tradable Cap2.47B	Total Shares206.40M
T/O37.76M	T/O Rate1.54%	Tradable Shares89.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMVT","market":"US","secType":"STK","nameCN":"Immunovant, Inc.","latestPrice":27.62,"timestamp":1792440000000,"preClose":26.73,"halted":0,"volume":1375251,"hourTrading":{"tag":"盘后","latestPrice":27.62,"preClose":27.62,"latestTime":"16:10 EDT","volume":28194,"amount":778718.28,"timestamp":1792440604740,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.033295922184811096,"floatShares":89566827,"shares":206402338,"eps":-2.817767,"marketStatus":"Post-Mkt","change":0.89,"latestTime":"10-19 16:35:54 EDT","open":27.12,"high":27.84,"low":26.525,"amount":37764664,"amplitude":0.049196,"askPrice":28.16,"askSize":71,"bidPrice":26.52,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-2.817767,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1792454400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":26.73,"preHourTrading":{"tag":"盘前","latestPrice":27.13,"preClose":26.73,"latestTime":"09:29 EDT","volume":4582,"amount":123869.60472,"timestamp":1792416599999,"change":0.4,"changeRate":0.014964,"amplitude":0.04826},"postHourTrading":{"tag":"盘后","latestPrice":27.62,"preClose":27.62,"latestTime":"16:10 EDT","volume":28194,"amount":778718.28,"timestamp":1792440604740,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.821259,"impliedVol":0.9112,"impliedVolPercentile":0.992},"requestUrl":"/m/hq/s/IMVT/tweets","defaultTab":"tweets","newsList":[{"id":"2676173527","title":"Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Immunovant (IMVT) and Thermo Fisher (TMO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2676173527","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676173527?lang=en_us&edition=fundamental","pubTime":"2026-10-18 20:50","pubTimestamp":1792327809,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on PTC Therapeutics (PTCT), Immunovant (IMVT) and Thermo Fisher (TMO...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ptc-therapeutics-ptct-immunovant-imvt-and-thermo-fisher-tmo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ptc-therapeutics-ptct-immunovant-imvt-and-thermo-fisher-tmo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0432979614.USD","GNMX","IE00BFTCPJ56.SGD","LU0011850046.USD","FMED","HRTS","LU0070302665.USD","LU1623119135.USD","LU2764263039.SGD","TMED","BK4548","LU0345770993.USD","LU0640476718.USD","LU0096362180.USD","IE00BQXX3D17.EUR","HCSG","LU2764262908.HKD","LU1267930573.SGD","BK4588","LU2023250504.SGD","LU1670627923.USD","LU0882574055.USD","TMO","BK4137","LU1815333072.USD","LU0342679015.USD","LU2106854487.HKD","PTCT","IE00B19Z8W00.USD","IMVT","LU0823416689.USD","LU2125909247.SGD","IE0009355771.USD","LU0528227936.USD","LU2720916845.USD","LU2041044095.USD","LU2112291526.USD","GB00BDT5M118.USD","XLV","XBI","LU1923622291.USD","LU0957791311.USD","LU2125909593.SGD","LABU","LU0708994859.HKD","LU1983299246.USD","LU0320765489.SGD","LU1720051017.SGD","LU1791710400.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674890551","title":"How Investors May Respond To Immunovant (IMVT) After Sjögren’s Trial Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2674890551","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674890551?lang=en_us&edition=fundamental","pubTime":"2026-10-10 23:36","pubTimestamp":1791646595,"startTime":"0","endTime":"0","summary":"Immunovant has come under pressure after Argenx reported a late stage failure in a Sjögren’s disease trial, raising fresh questions about the underlying approach for autoimmune therapies targeting this condition, including Immunovant’s mid stage IMVT-1402 program and its broader development priorities.\nThe setback follows Immunovant’s recent decision to discontinue a cutaneous lupus program after missing its main goal, which puts more weight on execution risk, trial design quality and...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/how-investors-may-respond-to-immunovant-imvt-after-sjgrens-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/how-investors-may-respond-to-immunovant-imvt-after-sjgrens-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMVT","BK4211","ISBC","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673006980","title":"Immunovant down after Argenx study fails in Sjogren’s disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2673006980","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673006980?lang=en_us&edition=fundamental","pubTime":"2026-10-08 23:00","pubTimestamp":1791471622,"startTime":"0","endTime":"0","summary":"Shares of Immunovant (IMVT), which has an ongoing Phase 2b Sjogren’s disease study, are down 6% to $30.05 in morning trading. Published first on Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunovant-down-after-argenx-study-fails-in-sjogrens-disease-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunovant-down-after-argenx-study-fails-in-sjogrens-disease-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4588","IMVT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673087032","title":"Immunovant CEO Eric Venker Disposes of Common Shares Worth $2.93 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2673087032","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673087032?lang=en_us&edition=fundamental","pubTime":"2026-10-06 07:43","pubTimestamp":1791243789,"startTime":"0","endTime":"0","summary":"Immunovant CEO Eric Venker disposes of common shares worth $2.93 millionImmunovant CEO and director Eric Venker increased his direct stake to 257,075 shares following CVAR settlement.92,187 shares wer","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL8Rvzcp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","PTH","ROIV","BK4585","IMVT","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672419217","title":"Roivant President and Immunovant CEO Eric Venker Disposes of 200,000 Common Shares Worth $7,324,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2672419217","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672419217?lang=en_us&edition=fundamental","pubTime":"2026-10-03 05:38","pubTimestamp":1790977094,"startTime":"0","endTime":"0","summary":"Roivant President and Immunovant CEO Eric Venker disposes of 200,000 common shares worth $7,324,000Roivant Sciences President and Immunovant CEO Eric Venker sold 200,000 common shares at a weighted-av","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL6N8y8r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","ROIV","IMVT","BK4007","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672553797","title":"Is Trial Failure Altering The Investment Case For Immunovant Stock (IMVT)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2672553797","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672553797?lang=en_us&edition=fundamental","pubTime":"2026-10-02 14:25","pubTimestamp":1790922306,"startTime":"0","endTime":"0","summary":"Immunovant reported topline data from a 57-patient proof-of-concept trial in cutaneous lupus erythematosus in which IMVT-1402 did not reach statistical significance on the primary CLASI A endpoint at Week 12, leading the firm to discontinue development for this indication.\nThe decision to halt CLE work concentrates Immunovant’s resources on autoimmune indications such as difficult-to-treat rheumatoid arthritis and Graves’ disease, where management is already planning larger, potentially...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/is-trial-failure-altering-the-investment-case-for-immunovant","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/is-trial-failure-altering-the-investment-case-for-immunovant","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","IMVT","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670474558","title":"Immunovant (IMVT) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2670474558","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670474558?lang=en_us&edition=fundamental","pubTime":"2026-09-26 22:35","pubTimestamp":1790433320,"startTime":"0","endTime":"0","summary":"In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Immunovant, with a price target of $53.00. According to Tip...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/immunovant-imvt-receives-a-rating-update-from-a-top-analyst-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/immunovant-imvt-receives-a-rating-update-from-a-top-analyst-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670256471","title":"Bernstein Reaffirms Their Hold Rating on Immunovant (IMVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670256471","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670256471?lang=en_us&edition=fundamental","pubTime":"2026-09-26 21:05","pubTimestamp":1790427914,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Eve Burstein from Bernstein maintained a Hold rating on Immunovant, with a price target of $37.00. The company’s sh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bernstein-reaffirms-their-hold-rating-on-immunovant-imvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bernstein-reaffirms-their-hold-rating-on-immunovant-imvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669702438","title":"Immunovant Down over 7%, on Pace for Largest Percent Decrease Since July 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2669702438","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669702438?lang=en_us&edition=fundamental","pubTime":"2026-09-24 01:52","pubTimestamp":1790185920,"startTime":"0","endTime":"0","summary":"Immunovant Inc.  is currently at $34.60, down $2.70 or 7.23%--Would be lowest close since June 16, 2026, when it closed at $33.61--On pace for largest percent decrease since July 25, 2025, when it fell 7.48%--Snaps a two day winning streak--Down 15.25% month-to-date; on pace for worst month since March 2025, when it fell 17.04%--Up 36.09% year-to-date--Down 34.37% from its all-time closing high of $52.71 on Nov. 17, 2020--Up 123.77% from 52 weeks ago , when it closed at $15.46--Down 23.05% from its 52-week closing high of $44.96 on Aug. 19, 2026--Up 123.77% from its 52-week closing low of $15.46 on Sept. 24, 2025--Traded as low as $33.60; lowest intraday level since June 16, 2026, when it hit $32.86--Down 9.9% at today's intraday low; largest intraday percent decrease since July 25, 2025, when it fell as much as 16.43%All data as of 1:49:41 PM ETSource: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669438224","title":"Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2669438224","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669438224?lang=en_us&edition=fundamental","pubTime":"2026-09-24 01:45","pubTimestamp":1790185500,"startTime":"0","endTime":"0","summary":"Immunovant shares were on track for their worst session in over a year after the biotech said it was halting development of its experimental autoimmune drug in one indication following a trial miss.Im","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4588","IMVT","BK4581","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669438452","title":"Analysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT), Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669438452","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669438452?lang=en_us&edition=fundamental","pubTime":"2026-09-24 01:30","pubTimestamp":1790184615,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunovant (IMVT) and Oruka Therapeutics (ORKA) with...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-immunovant-imvt-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-immunovant-imvt-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT","LABU","XBI","XLV","ORKA","LU0320765992.SGD","BK4581","HCSG","LU0109394709.USD","BK4139","BK4588","LU0889565916.HKD","LU0029874061.USD","BK4137","LU0128526141.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669810804","title":"Immunovant Proof-of-Trial for IMCT-1402 Misses Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2669810804","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669810804?lang=en_us&edition=fundamental","pubTime":"2026-09-23 22:19","pubTimestamp":1790173140,"startTime":"0","endTime":"0","summary":"Immunovant said it saw negative topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 imeroprubart for the treatment of cutaneous lupus erythematosus.The company said the study didn't achieve statistical significance on its primary endpoint of percent change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity score at Week 12.Immunovant said numerical trends favoring IMVT-1402 over placebo were observed across multiple endpoints, and patients who achieved deeper IgG reductions from baseline were more likely to achieve improved clinical responses. However, due to the competitive landscape and the clinical results observed, Immunovant plans to stop development in CLE.The company said it will still focus on advancing the clinical development of IMVT-1402 across multiple autoimmune diseases, including Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropat","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","IMVT","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669486413","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2669486413","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669486413?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:00","pubTimestamp":1790168425,"startTime":"0","endTime":"0","summary":"Healthcare stocks were steady premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF  slightly declining and the iShares Biotechnology ETF  inactive.Roivant Sciences  said its Immunovant  subsidiary plans to stop development of IMVT-1402 in cutaneous lupus erythematosus after a proof-of-concept study failed to achieve statistical significance on the primary endpoint. Shares of Immunovant and Roivant were down 6.1% and 1%, respectively, pre-bell.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ROIV","BK4137","IMVT","BK4581","XBI","LU0128526141.USD","BK4139","LU0029874061.USD","PTH","BK4585","IBB","HCSG","BK4007","XLV","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669372486","title":"Update: US Equity Futures Slightly Lower Pre-Bell as Traders Await Developments in US-Iran Talks","url":"https://stock-news.laohu8.com/highlight/detail?id=2669372486","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669372486?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:48","pubTimestamp":1790167737,"startTime":"0","endTime":"0","summary":"(Updates with economic data, recent oil price movements, world markets' overview, and corporate stock movements.)US equity futures were slightly lower pre-bell Wednesday as traders awaited development","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IONQ","ROIV","LU1670627923.USD","WQTM","BK4139","LU1670628061.USD","BHP","COAL","BK4566","BK4142","IONZ","CQTM","BK4170","BK4585","CART","IMVT","IONL","QTUP","LU0300736062.USD","IONC","BK4141","BK4588","BK4168","BK4591","SLX","LU0300736492.USD","BK4517","IOYY","LU0266013472.USD","LU1366192091.USD","IONX","CARX","WNDR","PTH","BK4113","BK4602","RCL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669483473","title":"Immunovant Falls After Lupus Drug Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2669483473","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669483473?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:04","pubTimestamp":1790165052,"startTime":"0","endTime":"0","summary":"BUZZ-Immunovant falls after lupus drug setback** Shares of biotech firm ImmunovantIMVT.Ofall 4.5% to $35.6 premarket** Stock set to open at its lowest level in over three months, if losses hold** Co p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nL6N45F0L8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4007","PTH","ROIV","BK4588","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669883024","title":"Roivant announces trial of IMVT-1402 did not reach statistical significance","url":"https://stock-news.laohu8.com/highlight/detail?id=2669883024","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669883024?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:10","pubTimestamp":1790161851,"startTime":"0","endTime":"0","summary":"Roivant announced topline results from Period 1 of Immunovant’s proof-of-concept trial evaluating IMVT-1402 for the treatment of cutaneous lupus er...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-announces-trial-of-imvt-1402-did-not-reach-statistical-significance-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-announces-trial-of-imvt-1402-did-not-reach-statistical-significance-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669810064","title":"Immunovant Announces Topline Results from Proof-of-Concept Study of Imvt-1402 in Cutaneous Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=2669810064","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669810064?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA7BQLZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMVT","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669618100","title":"Immunovant, - Imvt-1402 Study in Cle Did not Achieve Statistical Significance on Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2669618100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669618100?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA7BQLZP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMVT","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669210061","title":"Immunovant, - to Stop Development of Imvt-1402 in Cle","url":"https://stock-news.laohu8.com/highlight/detail?id=2669210061","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669210061?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA7BQLZP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMVT","BK4588","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669881004","title":"Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=2669881004","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669881004?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161200,"startTime":"0","endTime":"0","summary":"Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/23/3367346/0/en/immunovant-announces-topline-results-from-proof-of-concept-study-of-imvt-1402-in-cutaneous-lupus-erythematosus.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMVT","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunovant.com","stockEarnings":[{"period":"1week","weight":-0.1227},{"period":"1month","weight":-0.2653},{"period":"3month","weight":-0.3361},{"period":"6month","weight":-0.0877},{"period":"1year","weight":0.5353},{"period":"ytd","weight":0.0515}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":0.0122},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.1553},{"period":"ytd","weight":0.1193}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.081969},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.118937},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.068553},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.009383},{"month":5,"riseRate":0.428571,"avgChangeRate":0.091771},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.03669},{"month":7,"riseRate":0.625,"avgChangeRate":0.035685},{"month":8,"riseRate":0.625,"avgChangeRate":0.07742},{"month":9,"riseRate":0.75,"avgChangeRate":0.08416},{"month":10,"riseRate":0.625,"avgChangeRate":0.174427},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058678},{"month":12,"riseRate":0.714286,"avgChangeRate":0.132246}],"exchange":"NASDAQ","name":"Immunovant, Inc.","nameEN":"Immunovant, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunovant, Inc.,IMVT,Immunovant, Inc.股票,Immunovant, Inc.股票老虎,Immunovant, Inc.股票老虎国际,Immunovant, Inc.行情,Immunovant, Inc.股票行情,Immunovant, Inc.股价,Immunovant, Inc.股市,Immunovant, Inc.股票价格,Immunovant, Inc.股票交易,Immunovant, Inc.股票购买,Immunovant, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction